Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01455870 · ClinicalTrials.gov registry record · Phase 3

A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes

A Phase 3 study of Type 2 Diabetes, sponsored by Intarcia Therapeutics.

Completed
Registry status
Phase 3
Development phase
535
Enrollment target
20
Study locations

NCT01455870: Completed Phase 3 study of Type 2 Diabetes, sponsored by Intarcia Therapeutics.

NCT01455870 is a Phase 3 study of Type 2 Diabetes that has completed, run by Intarcia Therapeutics. The registered enrollment target is 535 participants, below the 3,922-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01455870, a Phase 3 study of Type 2 Diabetes, has completed, sponsored by Intarcia Therapeutics.

COMPLETED
Registry status
Phase 3
Development phase
535 participants
Enrollment target
20
Study locations

Study Summary

Phase 3 study to compare treatment with ITCA 650 to sitagliptin when added to metformin monotherapy in patients with type 2 diabetes.

Conditions Studied

Type 2 Diabetes

Interventions

  • DRUG sitagliptin
  • DRUG ITCA 650 60 mcg/day

Study Locations (20)

California

  • - Long Beach
  • - Los Angeles
  • - San Diego
  • - San Mateo
  • - Tustin
  • - Valley Village
  • - Walnut Creek

Florida

  • - Boca Raton
  • - Clearwater
  • - Coral Gables
  • - Miami
  • - North Miami Beach
  • - Pembroke Pines

Illinois

  • - Chicago
  • - Chicago

Indiana

  • - Avon
  • - Franklin

Alabama

  • - Birmingham

Arizona

  • - Chandler

Georgia

  • - Canton

Trial Details

FieldValue
Enrollment Target 535 participants
Start Date 2013-05
Est. Completion 2015-07
Phase Phase 3
Intarcia Therapeutics

16 total trials

What the finished NCT01455870 record still lists

NCT01455870 is an interventional study that assigns participants to a tested intervention. The registered 535 participants enrollment target is mid-sized for trials with a published cap, below the 3,922-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (86% lower).

The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which sitagliptin is the first listed.

NCT01455870 names 20 study sites across 7 states, led by California, Florida, Illinois.

Frequently Asked Questions

What is clinical trial NCT01455870 about?

NCT01455870 is a clinical study titled "A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes". Phase 3 study to compare treatment with ITCA 650 to sitagliptin when added to metformin monotherapy in patients with type 2 diabetes.

What is the current status of trial NCT01455870?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 535 participants. The study started on 2013-05. Estimated completion is 2015-07.

What conditions does trial NCT01455870 study?

This clinical trial studies the following conditions: Type 2 Diabetes.

What interventions are being tested in trial NCT01455870?

The interventions under investigation include: sitagliptin (DRUG), ITCA 650 60 mcg/day (DRUG).

Who is sponsoring clinical trial NCT01455870?

This trial is sponsored by Intarcia Therapeutics, which has 16 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01455870 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Type 2 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01455870's enrollment target sits among peer trials

535 43rd of 327 higher than 285 of 327 other Type 2 Diabetes trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05614739 · 535 participants · Phase 1

    FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3

  • NCT07091617 · 535 participants · NA

    Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer

  • NCT04910685 · 534 participants · Phase 2

    (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

  • NCT06128551 · 534 participants · Phase 1

    Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT01455870, the US trial registry maintained by the National Library of Medicine. NCT01455870 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.